SCHEMBL24838501

SCHEMBL24838501

CC(C)(CC(=O)O)C(C(=O)OCc1ccccc1)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
GAA P10253 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 3/20 0.42
USP2 O75604 1/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CTRB1 P17538 1/20 0.42
HSD11B1 P28845 1/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 1/20 0.42
ELANE P08246 1/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30683055 0.88 ALDH1A1 (0.40) ALDH1A1GAATDP1LMNAUSP2
SCHEMBL26932025 0.88 ALDH1A1 (0.40) ALDH1A1GAATDP1LMNAUSP2
SCHEMBL24838499 0.86 ALDH1A1 (0.43) ALDH1A1GAATDP1LMNAUSP2
SCHEMBL24838500 0.85 ALDH1A1 (0.42) ALDH1A1GAATDP1LMNAUSP2
SCHEMBL26932103 0.85 TDP1 (0.44) ALDH1A1GAATDP1LMNAUSP2
SCHEMBL30683090 0.85 TDP1 (0.44) ALDH1A1GAATDP1LMNAUSP2
SCHEMBL30683111 0.83 ALDH1A1 (0.40) ALDH1A1GAATDP1LMNAUSP2
SCHEMBL26932130 0.83 ALDH1A1 (0.40) ALDH1A1GAATDP1LMNAUSP2
SCHEMBL24838498 0.82 ALDH1A1 (0.44) ALDH1A1GAATDP1RAB9ACTRB1
SCHEMBL30683047 0.79 SYK (0.47) RAB9AMAPTPOLBL3MBTL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023239645-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
WO-2023239645-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
US-20230173078-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230173078-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-06-08 US disclosed
WO-2023278402-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 WO disclosed
WO-2023278402-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230173078-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 ALDH1A1 2230/4885GAA 323/4885TDP1 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.